oalib

Publish in OALib Journal

ISSN: 2333-9721

APC: Only $99

Submit

Any time

2019 ( 12 )

2018 ( 20 )

2017 ( 11 )

2016 ( 27 )

Custom range...

Search Results: 1 - 10 of 5576 matches for " Olga Agramonte Llanes "
All listed articles are free for downloading (OA Articles)
Page 1 /5576
Display every page Item
Uso del FVII activado recombinante en la enfermedad de Rendú-Osler-Weber o telangiectasia hemorrágica hereditaria y sangramiento digestivo: Primer caso comunicado en Cuba Use of recombinat activated factor VII in Rendú-Osler-Weber's disease or hereditary hemorrhagic talangiectasia and digestive bleeding: First case reported in Cuba
Olga M Agramonte Llanes,Delfina Almagro Vázquez,Heydi Garrote Santana,Sandra Sarduy Sáez
Revista Cubana de Hematolog?-a, Inmunolog?-a y Hemoterapia , 2008,
Abstract: El Factor VII activado recombinante (rFVIIa Novoseven, Novonordisk, Dinamarca) ha sido usado con éxito en el tratamiento de las hemorragias en pacientes hemofílicos con inhibidores, en la deficiencia congénita del FVII y en la tromboastenia de Glanzmann. Además, se ha planteado su uso en pacientes no hemofílicos con anticuerpos adquiridos contra el FVIII (hemofilia adquirida) y otros trastornos de la función plaquetaria como el síndrome de Bernard Soulier (SBS). Administrado en dosis farmacológicas aumenta la generación de trombina sobre las plaquetas activadas y puede ser beneficioso en otros trastornos caracterizados por sangramiento profuso e inadecuada generación de trombina como en las trombocitopenias. Ha sido usado en hemorragias secundarias a alteraciones de la función hepática y en el trauma severo. Su utilización en pacientes con enfermedad de Rendú Osler-Weber y sangramientos severos es una indicación nueva, teniendo en cuenta la activación de la coagulación en el sitio especifico de la lesión. Se reporta la respuesta favorable de un paciente con sangramiento digestivo severo con peligro para la vida en quien se utilizó rFVII en dosis de 90ìg/Kg hasta completar 3 dosis en 24 horas; se detuvo la hemorragia y se confirmó su carácter hemostático potente en sangramientos incontrolables The recombinat activated factor VII (rFVIIa Novoseven, Novonordisk, Denmark) has been successfully used in the treatment of hemorrhages in hemophilic patients with inhibitors, in the congenital deficiency of FVII and in Glanzmann's thromboasthenia. Besides, its use has been recommended in non-hemoplilic patients with acquired antibodies against FVIII (acquired hemophilia) and in other disorders of the platelet function as Bernard Soulier Syndrome (SBS). When it is administered at pharmacological doses, it increases the generation of thrombin on the activated platelet, and it may be benefitial in other disorders characterized by profuse bleeding and inadequate generation of thrombin, such as the thrombocytopenias. It has been used in hemorrhages secondary to alterations of the liver function and in severe trauma. Its administration to patients with Rendú Osler Weber's disease and severe bleedings is a new indication, taking into account the activation of coagulation in the specific site of the lesion. It is reported the favorable response of a patient with severe digestive bleeding endangering his life that received rFVII at doses of 90 μg/kg until completing 3 doses in 24 hours. The hemorrhage stopped and its potent hemostatic character in uncontrollable bleedings
Uso del factor VII activado recombinante en pacientes no hemofílicos en Cuba Use of the recombinant activated factor VII in non-hemophilic patients in Cuba
Olga Agramonte Llanes,Delfina Almagro Vázquez,José M Ballester Santovenia,Dunia Castillo González
Revista Cubana de Hematolog?-a, Inmunolog?-a y Hemoterapia , 2008,
Abstract: El factor VII activado recombinante (rFVIIa, NovoSeven ) ha sido utilizado en el tratamiento de los sangramientos en los pacientes hemofílicos con inhibidores. También ha sido usado para el tratamiento de los sangramientos no controlados asociados con trauma o cirugía. Se describe el tratamiento con rFVIIa en 7 pacientes no hemofílicos con un amplio rango de eventos hemorrágicos: 3 a quienes se les realizó trasplante hepático y presentaron sangramiento postrasplante sin respuesta al tratamiento convencional; 1 con aplasia medular severa y hemorragia retiniana; 1 con enfermedad de Rendú-Osler-Weber, quien tuvo un sangramiento gastrointestinal severo; y 1 paciente con manifestaciones hemorrágicas cutáneas y pulmonares debido a una enfermedad viral. La dosis de rFVIIa utilizada fue entre 90_100 μg/kg de peso, tanto para el tratamiento profiláctico como terapéutico. El rFVII activado alcanzó una hemostasia efectiva en todos los casos. Consideramos que el FVII activado puede ser aplicado cuando la combinación de los hemoderivados y los avances quirúrgicos han fallado en el control de los sangramientos que ponen en peligro la vida The recombinant activated factor VII (rFVIIa, NovoSeven ) has been used in the treatment of bleedings in hemophilic patients with inhibitors. It has also been used for treating uncontrolled bleedings associated with trauma or surgery. The treatment with rFVIIa in 7 non-hemophilic patients with a wide range of hemorrhagic events is described: 3 that underwent liver transplant and presented posttransplant without response to the conventional treatment; 1 with severe medullary aplasia and retinal hemorrhage; 1 with Rendú-Osler-Weber's disease that had severe gastrointestinal bleeding; and 1 patient with cutaneous and pulmonary hemorrhagic manifestations due to a viral disease. The dose of rFVIIa used was between 90 and 100 μg/kg of weight, both for the prophylactic and therapeutic treatment. The activated rFVII reached an effective hemostasis in all cases. We consider that the activated FVII may be applied when the combination of hemoderivatives and the surgical advances have failed in the control of bleedings endangering life
Enfermedad de Rendú-Osler-Weber: a propósito de 5 casos con epístaxis recurrente Rendú-Osler-Weber disease: apropos of 5 cases with recurrent epistaxis
Tahamara Alcalá-Villalón,Dunia Castillo-González,Olga Agramonte-Llanes
Revista Cubana de Hematolog?-a, Inmunolog?-a y Hemoterapia , 2012,
Abstract: Los pacientes con epístaxis representan entre el 10 y 12 % de los casos atendidos en los servicios de urgencia de otorrinolaringología. Se presentan 5 pacientes atendidos en este servicio del Hospital General Docente "Enrique Cabrera", en el período comprendido entre enero de 2010 a febrero de 2011 que fueron remitidos del Servicio de Hematología de dicho centro por episodios de epístaxis espontáneos y recurrentes, con historia familiar de sangramientos nasales. Todos presentaban la enfermedad de Rendú-Osler-Weber o telangiectasia hemorrágica hereditaria. Se describe el comportamiento de los sangramientos y se expone la asociación con trastornos de la función plaquetaria en 2 de ellos. Los resultados del tratamiento y seguimiento para controlar la hemorragia nasal fueron satisfactorios en los 5 casos. Patients with epistaxis represent 10 to 12 % of cases were seen at the emergency otolaryngology services. Five patients treated in this service at the General Teaching Hospital "Enrique Cabrera" from January 2010 to February 2011 were referred from the hematology service of this hospital due to episodes of spontaneous and recurrent epistaxis and family history of nasal bleeding. All of them had Rendu-Osler-Weber disease or hereditary hemorrhagic telangiectasia. We hereby describe the behavior of bleeding and present the association with platelet function disorders in two of them. The results of treatment and monitoring to control nosebleeds were satisfactory in all 5 cases.
Tratamiento con dosis moderada de hidroxiurea en la drepanocitosis Treatment with moderate doses of hydroxyurea in drepanocytosis
Sergio Machín García,Eva Svarch,Olga Agramonte Llanes,Aramís Nú?ez Quintana
Revista Cubana de Hematolog?-a, Inmunolog?-a y Hemoterapia , 2008,
Abstract: En el período comprendido entre junio del 2003 y junio del 2005 se trataron con hidroxiurea 45 pacientes con anemia drepanocítica; 16 ni os y 29 adultos, al menos con una de las manifestaciones siguientes: más de 3 crisis vasooclusivas (CVO) dolorosas al a o en los 3 a os previos al estudio, uno o más episodios de síndrome torácico agudo (STA) al a o en los 2 a os previos al estudio, o accidente vascular encefálico (AVE) en el a o anterior. La hidroxiurea se administró en dosis de 15mg/kg/día. El número de CVO dolorosas, STA, AVE, ingresos y transfusiones disminuyó significativamente (p<0,001). No hubo disminución de los parámetros hematológicos ni aumento de la creatinina o alaninoaminotransferasa. Se observo un incremento importante de los valores de hemoglobina fetal (p<0,008). No se presentaron manifestaciones tóxicas y el cumplimiento fue bueno. En este trabajo se demuestra que no es necesario utilizar la dosis máxima tolerada de hidroxiurea para obtener mejoría del cuadro clínico en la anemia drepanocítica, lo que tiene 2 ventajas: su toxicidad es menor y el tratamiento es menos costoso. Esto haría posible que un número mayor de ni os en los países de escasos recursos puedan beneficiarse con dicho tratamiento. From June 2003 to June 2005, 45 patients with drepanocytic anemia, 16 children and 29 adults, with at least one of the following manifestations were treated with hydroxyurea: more than 3 painful vasoocclusive crises (VOC) at a year and 3 years before the study, one or more episodes of acute thoracic syndrome (ATS) at a year and 2 years previous to the study, or vascular encephalic accident (VEA) in the previous year. Hydroxyurea was administered at doses of 15mg/kg/day. The number of painful VOC, ATS, VEA, admissions and transfusions decreased significantly (p<0.001). There was not either reduction of the hematological parameters or increase of creatinin or alanine aminotransferase. An important rise of fetal hemoglobin values (p<0.008) was reported. There were no toxic manifestations and the fulfilment was good. It was proved in this paper that it is not necessary to take the maximum tolerated dose of hydroxyurea to improve the clinical picture in drepanocytic anemia. Two of its advantages are its lower toxicity and the less expensive treatment. This would make possible that a greater amount of children in those countries with scarce resources may benefit from the treatment.
Deficiencia de proteínas C y S: marcadores de riesgo trombótico Deficiency of proteins C and S: trombotic risk markers
Yaneth Zamora-González,Olga M Agramonte-Llanes,Loreta Rodríguez-Pérez
Revista Cubana de Hematolog?-a, Inmunolog?-a y Hemoterapia , 2013,
Abstract: Desde hace varios siglos se conoce que los defectos de la coagulación causan enfermedades hemorrágicas, pero el estudio de su contraparte, las enfermedades trombóticas, se ha desarrollado con mayor profundidad hace solo algunas décadas. Son estos trastornos del sistema de la coagulación los que constituyen una de las causas más comunes de muerte en el mundo de hoy donde cada a o mueren alrededor de 2 millones de personas por trombosis, ya sea arterial o venosa. Además, se consideran una fuente importante de morbilidad en las personas que las padecen y sobreviven. Los estados de hipercoagulabilidad o trombofilias son condiciones clínicas que afectan a una serie de pacientes con tendencia anormal a presentar eventos trombóticos. La deficiencia de proteína C (PC) y proteína S (PS) constituyen causas de trombofilias congénitas o adquiridas que predisponen a la aparición de trastornos tromboembólicos, pérdidas recurrentes de embarazos, trombosis venosas recurrentes, entre otros. Su diagnóstico es de gran importancia porque permite realizar profilaxis para evitar el riesgo de recurrencia e informa sobre la posibilidad de un estado de portador en cualquier otro miembro de la familia. For several centuries it has been known that coagulation defects cause hemorrhagic disease, but the study of its counterpart, thrombotic diseases, has been developed in more depth just a few decades ago. These disorders of coagulation system are one of the most common causes of death in the world today, where about two million people die every year from thrombosis, either arterial or venous. They are also considered an important source of morbidity in people who suffer it and survive. Hypercoagulable state or thrombophilia are clinical conditions that affect a number of patients with abnormal tendency to thrombotic events. Deficiency of protein C (PC) and protein S (PS) are causes of congenital or acquired thrombophilias that predispose to thromboembolic disorders, recurrent pregnancy loss, recurrent venous thrombosis, among others. Its diagnosis is very important it provides tools for its prophylaxis in order to reduce the risk of recurrence and the possibility of identify a carrier state in any other family member.
Anemia drepanocítica y embarazo: transfundir o no transfundir, esa es la decisión Sickle cell anemia and pregnancy: to transfuse or not to transfuse, that's the decision
Carlos Hernández Padrón,Olga Agramonte Llanes,Roque Roque Frías,Onel ávila Cabrera
Revista Cubana de Hematolog?-a, Inmunolog?-a y Hemoterapia , 2006,
Abstract:
Nuevas estrategias en el tratamiento de la leucemia mieloide crónica
Pavón Morán,Valia; Jaime Fagundo,Juan Carlos; Agramonte Llanes,Olga; Hernández Ramírez,Porfirio;
Revista Cubana de Hematolog?-a, Inmunolog?-a y Hemoterapia , 2007,
Abstract: new therapeutic models have been recommended in the last years to be used in patients with chronic myeloid leukemia (cml) resistant or intolerant to imatinib. most of the models are based on interventions on specific sites of the signal transmission system that the cells used to send information to the nucleus. one of the strategies that has been incorporated is the use of farnesyl transferase inhibitors. therapeutic products that may be administered by oral route, due to the small size of their molecules, have already been identified. at present, there are 4 inhibitors in more advanced stages, mainly the r115777 (zarnestra, tipifarnib). the search for other tretament models gave rise to the appearance of new molecules that may be used to treat the cases of resistance or intolerance to imatinib, such as desatinib and dilotinib. other molecule under experimentation phase is that currently known as pkc 412 (n-benzoylstaurosporine), cgp41251 that is a powerful selective inhibitor of the protein kinase c isoforms . the development of the molecular therapeutics has advanced rapidly and its application to cml has attained very positive results that should increase with the incorporation of the new drugs under study and of those that will certainly emerge in the future
Uso del FVII activado recombinante en la enfermedad de Rendú-Osler-Weber o telangiectasia hemorrágica hereditaria y sangramiento digestivo: Primer caso comunicado en Cuba
Agramonte Llanes,Olga M; Almagro Vázquez,Delfina; Garrote Santana,Heydi; Sarduy Sáez,Sandra; Zamora González,Yaneth;
Revista Cubana de Hematolog?-a, Inmunolog?-a y Hemoterapia , 2008,
Abstract: the recombinat activated factor vii (rfviia novoseven, novonordisk, denmark) has been successfully used in the treatment of hemorrhages in hemophilic patients with inhibitors, in the congenital deficiency of fvii and in glanzmann's thromboasthenia. besides, its use has been recommended in non-hemoplilic patients with acquired antibodies against fviii (acquired hemophilia) and in other disorders of the platelet function as bernard soulier syndrome (sbs). when it is administered at pharmacological doses, it increases the generation of thrombin on the activated platelet, and it may be benefitial in other disorders characterized by profuse bleeding and inadequate generation of thrombin, such as the thrombocytopenias. it has been used in hemorrhages secondary to alterations of the liver function and in severe trauma. its administration to patients with rendú osler weber's disease and severe bleedings is a new indication, taking into account the activation of coagulation in the specific site of the lesion. it is reported the favorable response of a patient with severe digestive bleeding endangering his life that received rfvii at doses of 90 μg/kg until completing 3 doses in 24 hours. the hemorrhage stopped and its potent hemostatic character in uncontrollable bleedings was confirmed
Imatinib en leucemia mieloide crónica
Pavón Morán,Valia; Hernández Ramírez,Porfirio; Jaime Fagundo,Juan Carlos; Agramonte Llanes,Olga;
Revista Cubana de Hematolog?-a, Inmunolog?-a y Hemoterapia , 2005,
Abstract: chronic myeloid leukemia (cml) was the first neoplasia in which it was possible to present a model of genotype that served as a target for a molecular action therapy. the activation of multiple ways of transduction signals in the cells with the bcr-abl gene favors the increase of the cellular proliferation, interferes the apoptosis, and perturbs the interaction with the extracellular matrix and the stroma. the introduction of imatinib in the treatment of cml has modified the evolution and prognosis of this disease. imatinib has proved to have a high level of efficiency associated with a smaller number of adverse reactions on being compared with the regimens based on interferon and hydroxyurea
Nuevas estrategias en el tratamiento de la leucemia mieloide crónica New strategies in the treatment of chronic myeloid leukemia
Valia Pavón Morán,Juan Carlos Jaime Fagundo,Olga Agramonte Llanes,Porfirio Hernández Ramírez
Revista Cubana de Hematolog?-a, Inmunolog?-a y Hemoterapia , 2007,
Abstract: En los últimos a os se han propuesto nuevos modelos terapéuticos para ser utilizados en pacientes con leucemia mieloide crónica (LMC) resistentes o intolerantes al Imatinib. La mayor parte de estos modelos están basados en intervenciones sobre sitios específicos del sistema de transmisión de se ales que la célula utiliza para hacer llegar información al núcleo. Una de las estrategias incorporadas es el uso de inhibidores de la farnesiltransferasa y ya se han identificado productos terapéuticos factibles de ser utilizados por vía oral, debido al peque o tama o de sus moléculas. Actualmente hay 4 inhibidores en fases más avanzadas, fundamentalmente el R115777 (zarnestra, tipifarnib). La búsqueda de otros modelos de tratamiento dio lugar a la aparición de nuevas moléculas que pudieran ser utilizadas para tratar los casos de resistencia o intolerancia al Imatinib, entre estas el Desatinib y el Dilotinib. Otra molécula en fase de experimentación en casos de resistencia al Imatinib es la conocida actualmente como .PKC 412 (N benzil-estauroporina), CGP41251 que es un potente inhibidor selectivo de las isoformas de la proteincinasa C. El desarrollo de la terapéutica molecular ha avanzado rápidamente y su aplicación en la LMC ha logrado resultados muy positivos que se deben incrementar con la incorporación de los nuevos medicamentos en estudio y de aquellos que seguramente deben aparecer en un futuro New therapeutic models have been recommended in the last years to be used in patients with chronic myeloid leukemia (CML) resistant or intolerant to Imatinib. Most of the models are based on interventions on specific sites of the signal transmission system that the cells used to send information to the nucleus. One of the strategies that has been incorporated is the use of farnesyl transferase inhibitors. Therapeutic products that may be administered by oral route, due to the small size of their molecules, have already been identified. At present, there are 4 inhibitors in more advanced stages, mainly the R115777 (zarnestra, tipifarnib). The search for other tretament models gave rise to the appearance of new molecules that may be used to treat the cases of resistance or intolerance to Imatinib, such as Desatinib and Dilotinib. Other molecule under experimentation phase is that currently known as PKC 412 (N-benzoylstaurosporine), CGP41251 that is a powerful selective inhibitor of the protein kinase C isoforms . The development of the molecular therapeutics has advanced rapidly and its application to CML has attained very positive results that should increase with th
Page 1 /5576
Display every page Item


Home
Copyright © 2008-2017 Open Access Library. All rights reserved.